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Abstract: Nonsense-mediated mRNA decay (NMD) is a quality control mechanism that recognizes 
post-transcriptionally abnormal transcripts and mediates their degradation. The master regulator 
of NMD is UPF1, an enzyme with intrinsic ATPase and helicase activities. The cancer genomic 
sequencing data has identified frequently mutated residues in the CH-domain and ATP-binding 
site of UPF1. In silico screening of UPF1 stability change as a function over 41 cancer mutations has 
identified five variants with significant effects: K164R, R253W, T499M, E637K, and E833K. To 
explore the effects of these mutations on the associated energy landscape of UPF1, molecular 
dynamics simulations (MDS) were performed. MDS identified stable H-bonds between residues 
S152, S203, S205, Q230/R703, and UPF2/AMPPNP, and suggest that phosphorylation of Serine 
residues may control UPF1-UPF2 binding. Moreover, the alleles K164R and R253W in the  
CH-domain improved UPF1-UPF2 binding. In addition, E637K and E833K alleles exhibited 
improved UPF1-AMPPNP binding compared to the T499M variant; the lower binding is predicted 
from hindrance caused by the side-chain of T499M to the docking of the tri-phosphate moiety 
(AMPPNP) into the substrate site. The dynamics of wild-type/mutant systems highlights the flexible 
nature of the ATP-binding region in UPF1. These insights can facilitate the development of drug 
discovery strategies for manipulating NMD signaling in cell systems using chemical tools. 
Keywords: UPF1; ATP-binding site; UPF2; cancer mutations; structural stability; molecular 
dynamics simulations 
 
1. Introduction 
Non-sense mediated mRNA decay (NMD) is a quality-control checkpoint that detects and 
eliminates aberrant messenger RNAs (mRNAs) with premature termination codons (PTCs) [1–3]. As 
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such, the NMD complex can modulate the phenotypic outcome of genetic disorders caused by PTCs. 
Several studies have identified the existence of a transient ribosome associated complex containing 
eukaryotic release factor 1 (eRF1)-eRF3, up frameshift 1 (UPF1), ATP-dependent RNA helicase DEAH 
box polypeptide 34 (DHX34), and suppressor with morphological effect on genitalia 1 complex 
(SMG1C; containing SMG1 and its regulators SMG8 and SMG9) [4–9]. DHX34 dissociates DHX34-
UPF1-SMG1C from ribosome-associated eRF1-eRF3 and promotes its association with UPF2-UPF3-
EJC (exon junction complex) [5,9]. This may result in translation termination leading to the 
dissociation of the individual ribosomal subunits, release factors, and nascent protein. The UPF2 
protein binds with the N-terminal domain of the UPF1 protein, and releases this domain from the 
central core of UPF1 [9–11]. 
Several additional subunits in the NMD complex have relatively well-defined functions. The 
SMG1 protein has a kinase domain that phosphorylates the UPF1 residues from the N- and C-
terminal domains, and recruits the factors which initiate mRNA degradation by endonuclease 
cleavage (by SMG6), deadenylation (by the carbon catabolite repressor protein 4 (CCR4)-NOT 
deadenylase complex via the SMG5-SMG7) and/or decapping (by the decapping complex (DCPC) 
via Pro-rich nuclear receptor co-activator 2 (PNRC2)). UPF1 recruits DCPC independently of 
phosphorylation, and it has been suggested that recruitment of factors to the UPF1 phosphorylated 
C-terminal domain exclude this domain from the central core of UPF1 [9,12]. In addition, 
endonucleolytic cleavage, decapping, and deadenylation are sequentially carried out by complete 
mRNA degradation through the general cellular 5'–3' and 3'–5' exonucleolytic activities. 
Three proteins, UPF1, UPF2, and UPF3 constitute the core of this NMD complex and are highly 
conserved across species. UPF1, an RNA-dependent ATPase is the master regulator of NMD and its 
ability to selectively target PTC-containing mRNAs depends on its ATPase and helicase activities 
[4,13–16], and this function is regulated through phosphorylation of its N- and C-terminal domains 
[17,18]. At the structural level, UPF1 contains a modular domain organization, with a conserved 
cysteine-histidine-rich domain (CH-domain), followed by superfamily 1 (SF1) helicase region that 
includes two RecA-like domains (RecA1 and RecA2), which comprise the motor of the helicase[19–
21]. The CH-domain is stabilized by three zinc atoms bound by zinc finger-like motifs and the 
architecture of the CH-domain provides two distinct interfaces that bind to UPF2 (Figure 1A,B) 
[10,22]. Biochemical and structural analysis reveal that the complex of UPF2/UPF3 binds to the CH-
domain and causes a large conformational change, activating the ATPase or helicase activity of the 
UPF1 protein [11]. 
Biochemical analysis and structural studies of the UPF1-RNA complex highlight four important 
aspects in its dynamic function [11]: (i) specific interactions occur in the presence or absence of the 
CH-domain that drive either a closed or open conformation of UPF1; (ii) the mechanical relationship 
between UPF1-catalyzed ATP-hydrolysis and the UPF1 translocation along RNA has been analyzed; 
(iii) the crystal structures of UPF1 in a closed conformation have shown that the CH-domain does not 
directly interact with RNA, but rather induces the positioning of other domains of UPF1 towards the 
binding site; (iv) UPF2 protein binding to the CH-domain of UPF1 stimulates the helicase activity of 
the latter by triggering a large scale conformational change of the CH-domain and by disrupting the 
CH- and helicase-domain interactions (closed conformation), thus promoting an open conformation 
of UPF1 [11].  
Single amino acid mutations, residue changes, or single post-translational modifications such as 
the addition of phosphate or methyl groups at key sites within a protein may result in conformational 
changes, alterations of interaction networks, and hydrogen bond disruption, while these in turn may 
perturb the energy landscape. Moreover, mutation of an individual residue can affect or alter the 
kinetics of protein folding or cause protein aggregation and destabilization [23–26]. More than half 
of monogenic diseases are caused by single amino acid mutations and a common mechanism by 
which mutations cause human disease is protein stability change. This can result in enhanced or 
decreased protein degradation, mislocalization, or pathological re-wiring of its normal network by 
affecting protein–protein interactions. Approximately 88% of disease-associated non-synonymous 
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single nucleotide polymorphisms (nsSNPs) are found to be located in the pockets important for 
protein–protein interactions [23,27,28].  
 
Figure 1. UPF1 structure and mutations from different cancer types. (A) Crystal structure of UPF1 
(PDB: 2WJY [10]) representing different domains, ATP analogue (i.e AMPPNP), and Zn/Mg2+ ions. 
(B) Schematic model of UPF1 activation mechanism showing how the RNA binding and 
ATPase/unwinding activity are modulated by UPF2 in an NMD cycle. In the absence of UPF2, the 
UPF1 has extended RNA interactions via the RecA1, RecA2, 1B, and 1C domains and low  
RNA-unwinding properties. The CH-domain is displaced upon UPF2 binding (black dotted arrow) 
and domain 1B changes to a conformation where it does not clamp on the RNA 3' end and as a result, 
the RNA-unwinding activity is increased [11]. (C) UPF1 gene mutated in cancer, data retrieved from 
the cBioPortal database [29]. The frequency of a residue mutation equal to 2, 3, and 4 are marked in 
blue, green, and red boxes respectively. The mutations from the ATP-binding site are shown in 
orange. Color scheme: Zn and carbon in grey, Mg in green, oxygen in red, hydrogen in silver, nitrogen 
in blue, and sulfur in orange. 
The mutations located at the protein–protein binding interface could block the active site cleft, 
change binding affinity, and affect the structure of the protein complex. Therefore, in this study we 
focus on understanding the mutational landscape of the UPF1 protein in the structural context. 
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Particularly, we explore the structural impact of these mutations on UPF1 regions including the CH-
domain (important for UPF1-UPF2 binding) and the ATP-binding site (Figure 1). Previous studies 
have shown that disruption in the CH-domain could interfere with allosteric regulation [11]. In 
addition, simultaneous binding of UPF1 with ATP and RNA results in nucleotide-induced 
conformational changes in the ATP-binding and hydrolysis cycle, and the CH-domain regulates the 
extent of RNA binding by the helicase [11]. For the current study, we chose a subset of cancer 
associated mutations in the UPF1 protein from the cancer genomics database cBioPortal [29], and 
selected mutations that are located in the ATP-binding site or CH-domain of UPF1. Understanding 
how the mutations affect the stability of the UPF1 protein, and its interactions with ATP or with other 
proteins can provide new insights into the molecular mechanisms of this complex process and assist 
in drug discovery.  
An examination of the mutational landscape of UPF1 in cBioPortal [29] reveals a broad spectrum 
of mutations occurring in this protein in a range of cancer types (Table S1); the highest frequency is 
observed in endometrial and ovarian cancers. A key challenge is to understand which ones, among 
all these mutations, are likely to have a functional impact. Although the frequency of mutated sites 
or regions impacted can be used to classify the mutations as drivers, many mutations discovered so 
far are observed in a relatively small fraction of tumors [30]. In our study, we integrated 
computational methods that can predict the effects of variations on protein structure stability or 
interactions, and can help to identify functionally important mutations. In addition, those mutations 
showing considerable changes to structural stability were further studied by molecular dynamics 
simulations (MDS) as protein structures undergo a plethora of different motions that can be 
perturbed by post-translational modifications, mutations, or interactions with binding partners [31]. 
To investigate these biologically meaningful dynamic processes, MDS enables an atomic level 
description of the UPF1 protein conformations, typically difficult to be accessible through the static 
structures from X-ray crystallography. This MDS-enabled dynamic perspective may contribute to the 
elucidation of the associated molecular mechanisms. 
2. Results 
2.1. Effects of Mutations on the UPF1 Protein Stability 
The recurrent cancer mutations analysis in the UPF1 gene [29] using the cancer genome atlas 
(TCGA) sequencing data shows that 31 residues located in the UPF2 interacting domain (i.e. CH-
domain) of UPF1 and 10 residues at the ATP-binding site/substrate pocket were found to be 
frequently mutated (Figures 1 and S2). The UPF1 residues interacting with AMPPNP as well as 
residues around 8 Å of AMPPNP were characterized and mutation association with different cancer 
types was considered (Figure S2). Moreover, mutations retrieved from previous studies (C126S and 
F192E [4,7,11] in the CH-domain, and in the nucleotide-binding site: G495R, G497E, K498A, D636A, 
E637A, Q665A, R703A, and R865A [19,21,32,33]) were also subjected to our stability change 
calculations (i.e. for the UPF1 protein), in order to perform comparative analysis with the cancer 
mutations from cBioPortal [29]. In line with these observations, all mutations were generated and 
screened for changes in structural stability upon point mutations in UPF1 with respect to the wild-
type structure. The analysis was performed for UPF1 apo-form and for the UPF1 mutant models in 
complex with UPF2 or AMPPNP (Figure 2A). The mutations showing more negative (∆∆G) values 
compared to other variants, are those that result in improving the stability of the UPF1 protein (Figure 
2). 
Findings from the stability change suggest that the mutations C126S and F192E (from the  
CH-domain) destabilize the UPF1 protein (Figure 2A), and this correlates with the previous studies 
in which the C126S mutation abolishes the interactions between UPF1 and UPF2 [4,7], and the F192E 
mutation disrupts the hydrophobic pocket in the CH-domain and interferes with allosteric regulation 
[11,21]. 
In addition, previous studies of both yeast and human UPF1 have shown that the mutants 
K498A, D636A, and E637A were strongly defective for ATPase activity, but only K498A was defective 
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in ATP-binding [13,19,33]. As shown in Figure S2C, the residue K498 is involved in interactions with 
AMPPNP (tri-phosphate moiety) and the K498A mutant was not able to form any interaction with 
the AMPPNP molecule. This is consistent with the stability change analysis indicating that the K498A 
mutant destabilizes the UPF1 protein (Figure 2A). It is also known that the G495R/G497E mutants in 
the substrate pocket prevent dephosphorylation [32]; in our analysis, mutant G497E was found to be 
slightly destabilizing (Figure 2A). Additionally, the UPF1 mutants R703A and R865A are defective in 
both ATP-binding and hydrolysis, whereas the Q665A mutant nearly eliminated the ATPase activity 
[19]. In our findings for the wild-type system (Figure S2C), these residues were involved in the 
interactions with the tri-phosphate moiety of AMPPNP, and their mutations Q665A, R703A, and 
R865A destabilize the UPF1 protein and hinder their interactions with AMPPNP (Figure 2A). 
The individual variants resulting in significant structural changes and improvement in (i) the 
UPF1 protein stability, (ii) located in the binding interfaces of UPF1 with UPF2 and (iii) placed at the 
UPF1 binding interface to AMPPNP were selected for further detailed analysis by MDS (to identify 
molecular properties). In the CH-domain, theK164R and R253W alleles located at the UPF1-UPF2 
interface were analyzed by MDS. The K164R mutation is located at the UPF1-UPF2 interface while 
the R253W mutation is located at the boundary between the CH-domain and the helicase regions. As 
shown in Figure 2, UPF1 (CH-domain) residue R253 promotes its conformation between its apo-state 
and when in complex with UPF2. Therefore, MDS was used to explore whether this acts as a switch 
between the intramolecular interactions between the CH-domain and the helicase regions. 
Moreover, for the selection of mutations in the ATP/AMPPNP-binding region to be analyzed by 
MDS, a criteria was set to identify those mutations that improved the stability of the active form and 
destabilized the inactive form (apo-form) of the UPF1 protein, as well as those mutations located close 
to the phosphate groups of the AMPPNP molecule in the substrate binding pocket. We identified 
three mutants T499M, E637K, and E833K, of which the mutant E833K stabilizes UPF1 in complex 
with AMPPNP but not in its apo-form (Figure 2). The coupling of conformational changes to the 
nucleoside triphosphate, usually ATP-binding and hydrolysis is a general mechanism by which 
helicases and motor proteins catalyze physical transitions [19]. In conclusion, MD simulations can 
identify the conformational changes in UPF1 mutated at the ATP-binding site/substrate pocket 
(T499M, E637K, and E833K) and mutant at the interface with UPF2 (K164R and R253W). 
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Figure 2. Effects of mutations on the UPF1 protein. (A) UPF1 structural stability change (∆∆G; kJ/mol) 
upon mutation. In addition, the mutations from previous studies [4,7,11,13,19,21,32,33] are indicated 
by labels with the blue box. (B) The UPF1 structure showing mutations studied by MDS. The red 
arrows represent UPF1 mutations in the complex with UPF2/AMPPNP and the grey arrows show 
mutations in the apo-form of UPF1. Cα atoms of the wild-type and mutated residues are shown in 
grey and yellow, respectively (different domains of UPF1 are colored as per Figure 1). Color scheme: 
oxygen in red, hydrogen in silver, nitrogen in blue, and sulfur in orange. 
2.2. Molecular Dynamics Simulations 
The wild-type UPF1 protein was simulated in the apo-form as well as in the complex with UPF2 
or the non-hydrolyzable ATP analogue (AMPPNP). Five single mutations were studied in the 
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inactive apo-form of UPF1 and in the complex with UPF2 (K164R and R253W), or with AMPPNP 
(T499M, E637K, and E833K). 
2.2.1. UPF2 and AMPPNP Stabilizes the Wild-Type UPF1 
The time dependent changes in the root mean square deviation (RMSD) of the non-hydrogen 
atoms and the radius of gyrations (Figure 3A,B) suggest that the simulated systems attained stability 
around 400 ns. For the apo-form and UPF1-UPF2 or UPF1-AMPPNP simulations, the average RMSD 
values were between 8 and 9 Å and 6 and 7 Å, respectively (Figure 3). We next examined the root 
mean squared fluctuations (RMSF), a metric of residue flexibility, to measure the effects of UPF2 and 
AMPPNP binding (Figure 3C). All three wild-type systems (apo-form,  
UPF1-UPF2, and UPF1-AMPPNP) showed similar distributions (Figure 3C); high fluctuations were 
found in the CH-domain (the 116–295 region) of UPF1 that connects to the UPF2 protein (Figure 3C). 
 
Figure 3. Structural analysis of wild-type UPF1 in the MD simulations. (A), (B), and (C) RMSD, radius 
of gyration profile, and RMSF representing the structural changes and fluctuations of residues inthe 
UPF1 protein. (D) The protein motion corresponding to the first eigenvector defined on the basis of 
the combined trajectories (green is from the beginning, blue from 400 ns (where the system stabilized), 
and brown from the end of the MD). (E) and (H) Energy contribution of each UPF1 residue to the 
binding with UPF2/AMPPNP and the total binding energy for UPF1-UPF2/AMPPNP, calculated 
using MM-PBSA. Contribution of residues selected for mutation analysis are labelled and shown with 
black arrows in (E). (F) and (G) Number of hydrogen bonds formed between the CH-helicase domains 
(intramolecular UPF1) and between UPF1-UPF2/AMPPNP (intermolecular). The dark lines represent 
the moving average of H-bonds formed with a period of 10 ns (i.e. number of H-bonds averaged every 
10 ns). 
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The radius of gyration (Rg) is an indicator of the protein secondary structure compactness. Rg 
measures the mass of atoms relative to the center of the mass of a protein or molecule; higher values 
of gyration indicate less compactness. The wild-type structure of UPF1 was found to be less compact 
in complex with UPF2 or AMPPNP compared to that of the apo-state (Figure 3B). Presentation of 
potential motions projected along the first eigenvector or the principal component showed that the 
absence of any interacting partner (UPF2 or AMPPNP) drives the movement of the UPF1 CH-domain 
towards the helicase-domain as shown in Figure 3D. Moreover, the number of hydrogen bond 
interactions was generally constant for all systems, implying successful equilibration of the CH-
helicase domain interactions as well as the UPF1-UPF2 interactions (Figure 3F,G). In the apo-state of 
the UPF1 protein, the CH- and helicase-domains engage in a relatively higher number of H-bonds 
and were found to be reduced in complex with UPF2 or AMPPNP. This observation correlates with 
a previous study suggesting that binding of UPF2 with the UPF1 CH-domain, disrupts the 
interactions of the CH-domain with the catalytic helicase-domain, which then promotes the UPF1 
helicase activity [11]. The interactions of UPF1 with UPF2 and with AMPPNP were stabilized 
throughout the simulation by about eight and five hydrogen bonds, respectively (Figure 3G). 
From the equilibrated trajectories of UPF1-UPF2 or UPF1-AMPPNP simulated systems, the 
binding free energy (∆Gbind) was computed for the snapshots (structures) collected every 1 ns, using 
the molecular mechanics/Poisson–Boltzmann surface area (MM-PBSA) method. The findings 
obtained from this approach can help to better understand the interaction pattern of UPF1 with UPF2 
or AMPPNP, as well as unveil the hot spot residues of UPF1 that were common in the  
wild-type and mutant systems. The averaged ∆Gbind for the UPF1-UPF2 complex was –1122 kJ/mol 
(Figure 3A) and for the UPF1-AMPPNP complex was –339 kJ/mol (Figure 3H), considering the 
stabilized systems. The residue level contributions in binding energy suggest that the residues  
116–296 of UPF1 (CH-domain) make significant contributions to the interactions with UPF2  
(Figure 3E) and the residues within the range 438–896 in UPF1 (helicase-domain; RecA1 and RecA2) 
showed significant contributions to the interactions with AMPPNP. Moreover, these results are 
consistent with previous studies [11], demonstrating that the CH-domain contributes to UPF2 
binding, and the RecA1 and RecA2 domains contribute to substrate binding. 
Furthermore, the intramolecular H-bonds (within UPF1) formed between the CH- and helicase-
domains were analyzed (Table S2), and the H-bond occupancy was defined as the percentage of the 
total simulation time a specific H-bond existed. The findings suggest that two interacting pairs of 
residues (CH/helicase) were found to be common in the apo-form and in the UPF1-UPF2 complex: 
R253/Y300 and R253/V437, respectively. In addition, the common interacting pair of residues in the 
apo-form and in the UPF1-AMPPNP complex was R253/A431. Residues R253 and E278 of the CH-
domain, and Tyr300 of the helicase-domain of UPF1 were found to be engaged in intramolecular H-
bond interactions in all three simulated systems. Residues of the CH- or helicase-domain making a 
long-lasting interaction network are presented in the Table S2. As shown in Table S3, most of the 
intermolecular interactions (UPF1-UPF2 or UPF1-AMPPNP) are characterized by high H-bond 
occupancy which suggests stable as well as conserved interactions. The UPF1 residues S152, S203, 
and V205 formed stable H-bonds with UPF2 with occupancy ≥40%, and residues G495, K498, and 
T499 were engaged in H-bonds with the AMPPNP molecule having occupancy ≥50% (Table S3). 
2.2.2. Effects of Cancer Variants in the ATP-Binding Pocket of UPF1  
Three single amino acid mutations (T499M, E637K, and E833K) in the ATP-binding site/substrate 
pocket of UPF1 were studied by the MDS approach. All three mutants showed different deviations 
in the apo-state and when bound with AMPPNP. For the UPF1 mutants E637K/E833K, RMSDs were 
higher for the apo-form with sudden spikes, whereas the RMSD remained relatively stable for UPF1 
in complex with AMPPNP. A contrasting behavior was observed in the case of the mutant T499M, 
with RMSD values higher by about 5 Å for the UPF1-AMPPNP complex compared to the apo-form 
(Figure 4A). The PCA data suggests greater movements of the CH-domain in the UPF1 mutants 
T499M and E833K when complexed with AMPPNP, whereas this domain was relatively stable in the 
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apo-state. In the case of the E637K mutant, the structure of UPF1 has increased motions in the apo-
form compared to that in complex with AMPPNP (Figure 4B). 
 
Figure 4. Structural analysis of T499M, E637K, and E833K mutants in the UPF1 protein. (A) RMSD for 
all atoms (excluding hydrogens) of mutant UPF1. (B) The principal motion projected along the first 
eigenvector defined on the basis of the combined trajectories (green marks the beginning and brown 
is the end of MDS; yellow are residues within 5 Å of the mutated residues). (C) RMSD for all atoms 
(excluding hydrogens) of AMPPNP from the WT and mutant UPF1-AMPPNP systems. (D) and (E) 
Number of hydrogen bonds formed between CH-helicase domains (UPF1 intramolecular) and 
between UPF1-AMPPNP (intermolecular). The dark lines represent trends with a moving average of 
H-bonds formed with a period of 10 ns (i.e. number of H-bonds averaged every 10 ns). (F) and (G) 
Energy contribution (computed using MM-PBSA) of each residue of UPF1 to the binding with 
AMPPNP and total binding energy for UPF1-AMPPNP complex, respectively. Contribution of 
residues selected for mutational analysis are labelled and shown with arrows in (F). 
Moreover, for the AMPPNP molecule, sudden spikes in RMSDs were observed when complexed 
with the UPF1 mutant systems E637K or E833K, and these jumps arise from the rotations of the 
aromatic rings of AMPPNP or its movement within the UPF1 substrate pocket. In addition, for the 
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mutant T499M system, the RMSD of AMPPNP reached ~2.5 Å and then remained stable throughout 
the MD simulation (Figure 4C).  
For all UPF1 substrate pocket mutant systems (T499M, E637K, and E833K), the average number 
of H-bonds formed between the CH- and helicase-domains was in the range of ~4–8 (Figure 4D), and 
the residues making long-lasting interactions were also identified (Table S4). The higher number of 
residues were identified as engaging in high occupancy intramolecular (between CH-helicase 
domains) H-bond interactions in the apo-form of mutant UPF1 (T499M/E833K) compared to the 
mutant systems bound with AMPPNP (Table S4). In addition, the average number of intermolecular 
H-bonds formed between AMPPNP and mutant UPF1 (T499M/E637K/E833K) was around three 
(Figure 4E). However, in the mutant T499M system, a slightly lower number of H-bonds (average 
~2.7) were formed with the AMPPNP molecule (Figure 4E). 
Using the MM-PBSA approach, the binding energy between AMPPNP and UPF1 substrate 
pocket mutants were estimated (the entropic contributions in the binding energy were not included; 
Figure 4F,G). The ability of UPF1 to interact with the ATP analogue was found to be similar in the 
E637K and E833K mutant systems, with ∆Gbind average of around –900 to –1000 kJ/mol, whereas a 
slightly lower ∆Gbind (average: –833 kJ/mol) was observed for UPF1-AMPPNP in the T499M mutant 
system (Figure 4G). In addition, to obtain a more-detailed insight into the binding of AMPPNP to the 
three UPF1 mutant systems, the ∆Gbind was further decomposed into individual residue 
contributions. As shown in Figure 4F, UPF1 residues contributing significantly to binding AMPPNP 
belonged to the RecA1 and RecA2 regions of UPF1 in all systems. 
The radius of gyration (Figure S3) ranged between ~29–32 Å for the UPF1 substrate mutant 
systems, and overall the RMSFs exhibited similar trends in conformational flexibilities, ranging 
between 2–4 Å. The CH-domain (residues 116–236) of UPF1 had relatively higher RMSFs of up to 8 
Å in all systems, and this higher flexibility is likely due to the absence of UPF2 in the system (Figure 
S3). RMSFs for each mutated residue were compared with their behavior in wild-type UPF1 in the 
apo-state and bound to AMPPNP (Figure 5A). The residues T499 and E833 in the wild-type UPF1 
protein showed slightly higher fluctuations when bound with AMPPNP compared to the apo-form, 
whereas these residues in the UPF1 mutant showed higher RMSFs when in the apo-form compared 
to the AMPPNP bound systems. In addition, the RMSF ofE637 was ~1 Å in the apo-state and 
AMPPNP bound forms in both wild-type and mutant UPF1 (Figure 5A). 
The UPF1 residues contributing ≤–80 kJ/mol (∆Gbind) to the total binding energy with AMPPNP 
were identified, and their behavior was compared with other simulated models. Almost all of the 
residues in the mutant protein exhibited similar contributions to binding AMPPNP as those of the 
wild-type UPF1, except E637 and E833 which contributed more in their mutant forms E637K and 
E833K, respectively, compared to their native form (Figure 5B). 
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Figure 5. Molecular properties of the UPF1-AMPPNP model systems. (A) Substrate binding site 
residues of the UPF1 protein and studied mutations. RMSFs for wild-type UPF1, mutant models; apo-
form and AMPPNP bound UPF1. (B) Individual residues of UPF1 contributing to the binding energy 
for AMPPNP, calculated by MM-PBSA. (C) Binding mode of AMPPNP to the UPF1 protein in 
different model systems, and UPF1 residues forming stable H-bonds with AMPPNP having 
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occupancy ≥10%. (D) Binding conformation of AMPPNP with respect to the wild-type and mutated 
UPF1 (T499M, E637K, and E833K) obtained from the end of MDS. 
Interactions and the binding pattern analysis of AMPPNP showed that the tri-phosphate moiety 
of the AMPPNP molecule (Figure 5C) engages with a range of residues in the wild-type and mutant 
systems. Particularly, the residue R703 of the UPF1 protein formed hydrogen bond interactions with 
the AMPPNP in the wild-type as well as in all mutant systems (T499M, E637K, and E833K). Residues 
of UPF1 that formed H-bond interactions with AMPPNP in the wild-type and in the E637K and 
E833K mutant models were: G495, T496, and G497 (Figure 5C). In addition, the residue K498 was 
found to be engaged in H-bonds with the AMPPNP in the wild-type, T499K, and E833K systems, 
whereas the residues T499 and K533 were involved in H-bond interactions with AMPPNP in the 
wild-type and E637K systems (Figure 5C). Residue G831 formed H-bonds with AMPPNP in the wild-
type as well as in T499M models, and R865 formed H-bonds with AMPPNP in T499M and E637K 
mutant systems (Figure 5C and Table S5). Analyzing the interactions of mutated residues (T499M, 
E637K, and E833K) with AMPPNP (Figure 5C) identified interactions with residues K637 and K833 
but not with the M499 mutant. 
Findings from MDS suggest that the wild-type and mutant UPF1-AMPPNP complexes showed 
significant differences in the conformations of the AMPPNP molecule in the substrate binding pocket 
of UPF1, particularly, in the mutant T499M (Figure 5D). By contrast, the other two mutant model 
systems E637K and E833K exhibited slight movements observed for AMPPNP, but lacked any 
significant conformational shift as that seen for the T499M system (Figure 5D). To understand this 
difference in the AMPPNP conformation, we traced the dynamics of the mutated residues in the apo-
form and in the UPF1-AMPPNP bound form (Figure S4). Analyzing the wild-type systems, the 
dynamics of all three residues T499, E637, and E833 showed almost similar conformations in the apo-
form and AMPPNP bound forms (Figure S4). In addition, for the E637K or E833K mutant model 
systems, the conformations of the mutated residues K637 or K833 in the apo-state correlated with the 
AMPPNP-bound systems. By contrast, the mutated residue M499 showed different conformations in 
the apo-form and AMPPNP-bound form (Figure S4). The dynamics of AMPPNP and the mutated 
T499M residue suggest that after mutation the residue M499 reduces the stabilization of the tri-
phosphate moiety of the AMPPNP in the substrate binding site of UPF1 (Figure 5D). This suggests 
that the T499M mutation may also affect the ATP-binding/hydrolysis process of the UPF1 protein or 
the NMD machinery. 
2.2.3. CH-Domain Mutants Enhance UPF1-UPF2 Binding 
MDS was used to investigate how mutations in the UPF1 CH-domain affect its binding and 
interactions with UPF2. The RMSD for both UPF1 mutants in the apo-form as well as in complex with 
UPF2 were found to vary between ~5 and 7 Å. In case of the mutant R253W, the RMSD remained 
relatively stable during the last 500 ns, whereas for the UPF1 with mutation K164R, the stable 
behavior was observed after ~600 ns (Figure 6A). Similarly, the K164R mutant had similar RMSD 
statistics for the apo-form and UPF1-UPF2 complex. In addition, for the R253W simulation, RMSD 
was higher by ~2 Å for UPF1 in complex with UPF2 compared to the apo-state (Figure 6). 
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Figure 6. Structural analysis of UPF1 mutants K164R and R253W. (A), (B), and (C) RMSD, RMSF, and 
radius of gyration profiles representing structural changes and fluctuations of UPF1 residues. (D) The 
motion corresponding to the first eigenvector defined on the basis of the combined trajectories. (E) 
and (F) Number of hydrogen bonds formed between CH-helicase domains (UPF1 intramolecular 
interactions) and between UPF1-UPF2 (intermolecular interactions). The dark lines represent trend 
with a moving average of H-bonds formed with a period of 10 ns (i.e. number of H-bonds averaged 
every 10 ns). (G) and (H) Energy of each residue (of the mutant UPF1) contributing to the binding 
with UPF2 and total binding energy for UPF1-UPF2, calculated by MM-PBSA. 
RMSF for each residue in UPF1 showed that the residues ranging from 116–295 of the  
CH-domain fluctuate more than any other region of the protein, and peaks represent the local 
fluctuations along the protein (Figure 6B). In the mutant UPF1-UPF2 systems, particularly in R253W, 
residues in the range 210–230 (from CH-domain) showed less fluctuations compared to the wild-
type, as this region makes interactions with the UPF2 protein (Figures 6B and 7). For the 
UPF1(K164R)-UPF2 system, some regions in the helicase-domain show high fluctuations compared 
to the UPF1(R253W)-UPF2 system; this can be due to lack of CH-helicase (intramolecular) 
interactions in the K164R system that were observed in the R253W system (Figure 7). Moreover, UPF2 
interacts with the mutated K164R residue and to achieve this interaction, the UPF2 protein adopts a 
slightly different (bent) conformation which resulted in the loss of some interactions with UPF1 in 
the vicinity of the CH-helicase domain (Figures 6B and 7). 
The radius of gyration was computed for mutant models to observe the conformational 
alterations of the K164R and R253W mutants in their apo and UPF2 bound forms. The structure of 
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mutant UPF1 (K164R/R253W) in its apo-form exhibited lower Rg values compared to that with UPF2, 
suggesting that in its apo-state the mutant is more compact (Figure 6C). 
In the eigenvalue projections (PCA), the clusters were more well defined for UPF1 mutants 
complexed with UPF2, whereas in the apo-form, regions of mutant UPF1 close to the CH-domain had 
larger movements (Figure 6D). The analysis of H-bond interactions formed between the CH- and 
helicase-domains of UPF1 shows that the number of these intramolecular interactions were 
conserved with ~4–8 hydrogen bonds in all simulated systems (Figure 6E). The common residues of 
CH-domain interacting with helicase-domains in the mutant apostate (K164R/R253W) were: 
R253/W253, R255, T258, Q261, and L293. In addition, for the mutant (K164R/R253W) UPF1-UPF2 
complexes, residues T258, Q260, Q261, and D279 of the CH-domain were found to be engaged in 
intramolecular H-bonds. In the helicase-domain, residues that formed H-bonds with the CH-domain 
in the mutant (K164R/R253W) apo-state were: Y296, E297, and D298. Residues E297, D298, and Y300 
of the helicase-domain formed H-bonds with the CH-domain in both mutant UPF1(K164R/R253W)-
UPF2 complexes (Table S6). 
The average number of H-bonds formed between mutant UPF1-UPF2 was in the range of ~8–10 
for K164R and ~14–16 for R253W systems, and these numbers were maintained throughout MDS 
(Figure 6F). The total binding energy (contribution from the van der Waals, electrostatic, polar, and 
non-polar interactions) for UPF1-UPF2 was found to be almost similar, –1200 to –1400 ∆E (kJ/mol) in 
the case of both mutant models, K164R and R253W (Figure 6G). Moreover, a quantitative assessment 
of the binding energy at individual residue level shows that in both UPF1(K164R/R253W)-UPF2 
systems, the residues with high contributions are placed in the CH-domain (residues ranged 116–
296; Figure 6H).  
Four intermolecular (UPF1-UPF2) H-bond interactions were found to be common in both 
complexes of UPF1(K164R/R253W)-UPF2 (Table S7), and these common H-bonds suggest stable as 
well as conserved interactions. The interacting pairs of residues UPF1-UPF2 were as follows: S152-
D1110, S203-V1172, V205-V1172, and V205-L1174, respectively. Moreover, the individual residues 
Q230 of UPF1 as well as N1124 and Q1127 of UPF2 were found forming common intermolecular H-
bond interactions in both K164R or R253W systems. Globally, the UPF1(R253W)-UPF2 interactions 
were more stable with relatively high H-bond occupancy compared to the UPF1(K164R)-UPF2 
interactions (Table S7). 
RMSFs for the specific UPF1 residues (K164 and K253) and their structural fluctuations in 
mutated systems were compared with the wild-type systems in both apo as well as UPF1-UPF2 
complexes. The findings suggest that both residues K164 and K253 of wild-type UPF1 showed 
slightly higher fluctuations in complex with UPF2 compared to the apo-form, whereas these residues 
undergo similar fluctuations in mutant models whether UPF1 was in the apo-state or was UPF2 
bound (Figure 7A). Our findings suggest that UPF1 residues R148, R210, R236, and R295 contributed 
similar binding energies to UPF2 in wild-type as well as in mutated systems (Figure 7B). 
The binding mode of UPF1-UPF2 proteins and residues of CH-domain forming stable 
(occupancy ≥10%) H-bonds with UPF2 in different model systems are highlighted in Figure 7C. 
Interacting (H-bond) residues common to all three UPF1-UPF2 complexes were S152, S203, S205, and 
Q230. Furthermore, residues N190 and Q228 of UPF1 interacting with UPF2 were found common in 
wild-type and K164R systems. In addition, the L207 residue of UPF1 formed interactions with UPF2 
in the wild-type and R253W systems (Figure 7C). The binding mode of the UPF1 with UPF2 protein 
as well as the conformation of the residues K164 and R253 binding in their native and mutated forms 
(R164 and W253) are shown in Figure 7D. 
Figure S5 represents RMSDs of the UPF2 protein from different simulated systems, and it was 
observed that the RMSD of UPF2 remained almost stable after ~500 ns in all three complexes  
(wild-type/K164R/R253W). The RMSD of the UPF2 protein in complex with mutant 
UPF1(K164R/R253W) was higher by ~1–2 Å compared to its complex with the wild-type UPF1. In 
addition, a quantitative assessment of the binding energy of individual residues was also performed 
for the UPF2 protein, and the residues of UPF2 with high contributions to binding UPF1 wild-
type/mutant models were also identified (Figure S5). 
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Figure 7. Detailed analysis of UPF1-UPF2 model systems. (A) UPF1 residues involved in binding with UPF2 and 
their mutations. RMSF values were calculated in native or wild-type UPF1, mutant models, apo-form, and UPF1 
bound with UPF2. (B) Individual UPF1 residues contributing to the binding energy with UPF2, were computed 
using MM-PBSA. (C) Interactions of UPF1 with UPF2 in different model systems, and residues of UPF1 forming 
stable H-bonds with UPF2 having occupancy ≥10%. (D) Binding mode or conformation of the UPF1 residues 
(K164 and R253 in native or mutated form R164 and W253) with UPF2 (Color scheme: green represents wild-
type and yellow mutated systems, carbon in green/yellow, oxygen in red, nitrogen in blue, and hydrogen in 
silver). 
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2.2.4. Conformations of the Wild-Type and Mutant Systems 
The structural transitions of the UPF1 protein were analyzed from the beginning and end of the 
MD simulations. There is considerable conformational flexibility observed in some regions of UPF1, 
mostly the CH-domain situated at the interface interacting with UPF2 and in the domains 
binding/close to AMPPNP (Figure 8). For the systems with UPF2, the CH-domain of UPF1 
maintained its native structure which suggests that the intermolecular interactions of UPF1-UPF2 are 
required for maintaining the native state conformation. Moreover, concerning the  
UPF1-AMPPNP complexes, the CH-domain does not undergo much movement in its wild-type form, 
whereas in all three substrate pocket mutant models, this region is mobile in the direction of the 
helicase-domain (Figure 8). 
Comparing the dynamics of UPF1 substrate pocket mutants: T499M, E637K, and E833K it is 
apparent that the CH-domain undergoes more conformational changes in its AMPPNP bound form 
when compared to its apo-form (Figure S6). Moreover, the subdomain rearrangements in the UPF1 
substrate pocket mutant models describe that the CH- and helicase-domains develop their spatial 
proximity in the presence of AMPPNP, and such behavior was not seen in any of the other simulated 
systems (Figures 8 and S6). This analysis suggests that motions of the CH-domain are directly affected 
by the mutations in the substrate pocket of UPF1, and also hint at the complex nature of allosteric 
transitions. For example, it is possible that the substrate binding site mutations enable the CH-domain 
to move towards the helicase region such that the AMPPNP molecule would be stuck in the ATP-
binding site, which can affect or stop the hydrolysis reaction. 
The compactness or flexibility of the substrate pocket were analyzed by calculating an area 
encompassed by selecting the Cα atoms (xyz coordinates) of a set of three residues T499, E637, and 
E833. The area computed can serve as a measure of the open and closed spaces accessible to the ATP 
ligand or its analogues (e.g. AMPPNP; Figure 8B). For the wild-type and mutant E637K systems, the 
area computed between the three residues was in the range of around 5–10 Å2, whereas for the T499M 
and E833K mutant systems frequent jumps were observed in these values. Particularly, in case of the 
T499M system the area increased significantly, reaching up to ~20 Å2 in the apo state and ~25 Å2 in 
the AMPPNP bound system by the end of MDS. During the initial part of the simulation of the E833K 
system, the area occupied by the substrate binding region in the UPF1 protein was considerably 
different for the apo-form and AMPPNP bound form, but later (600–1000 ns), this region became 
more compact in both systems (Figure 8).  
Furthermore, the area accessible by the three residues T499, E637, and E833 (of the ATP-site) in 
the UPF1 protein when complexed with UPF2 differs between the apo-form and UPF1-UPF2 systems 
as shown in Figure S7. In apo systems (wild-type/K164R/R253), this area was around 10 Å2, and for 
the wild-type UPF1-UPF2 complex the area ranged between 40 and 60 Å2. Concerning the 
UPF1(K164R)-UPF2 complex, the area occupied was about 60 Å2 initially, but eventually converged 
to ~30 Å2. In addition, the UPF1(R253W)-UPF2 system had the highest area (~90 Å2). These variations 
in area reflect the flexible nature of the ATP-binding region in the UPF1 protein, and this underscores 
how this region can undergo induced fit in order to accommodate the AMPPNP molecule (Figures 
S7 and 8). 
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Figure 8. Structural/conformational changes of UPF1 protein when complexed with UPF2 or 
AMPPNP. (A) Wild-type and mutant UPF1 protein in complex with AMPPNP or UPF2. (B) Area 
analysis of structural changes in the ATP-binding region of the UPF1 protein, triangle selected for 
area calculation was based on Cα atoms coordinates of T499, E637, and E833 residues. The dark lines 
Int. J. Mol. Sci. 2019, 20, 5644 18 of 24 
 
represent the trend with a moving average of area with a period of 10 ns. Different domains of UPF1 
are colored as per Figure 1. 
3. Discussion 
The UPF1 protein is a master regulator of NMD machinery, and the ability of NMD to selectively 
target PTC-containing mRNAs depends on the ATPase and helicase activities of UPF1. In addition, 
the UPF1 and UPF2 proteins contribute/constitute the core of the NMD pathway. NMD can have 
impacts on health; for example, the accumulation of mutated mRNA can lead to enhanced production 
of mutant proteins that can result in increased disease incidence [34]. In addition, the inhibition of 
NMD can allow the re-expression of mutant proteins in cancer models and can stimulate tumor death 
[35]. These latter data suggest that the NMD protein components could form a therapeutic target in 
selected human cancers. Indeed, the inhibition of NMD in mouse models can cause anti-tumor 
immunity through the production of tumor-specific T-cells that target neo-antigens on the surface of 
cancer cells [36]. However, targeting NMD could be complicated by whether or not NMD pathway 
components are mutated in human cancers. In this study, we set out to first determine whether the 
NMD pathway component UPF1 was in fact mutated to a degree in human cancers; and if so, what 
the effects of these mutations might be on the protein function. For example, mutations could be loss 
or gain-of-function, depending upon the reaction cycle and mode of action of each regulatory 
domain. This information is important to facilitate drug-discovery screens aimed at inhibiting tumor 
cell growth or stimulating neoantigens that can promote anti-tumor immunity.  
Using the large annotated multi-tumor cancer genome sequencing resource, we identified 41 
mutations (31 residues in the CH-domain and 10 residues at the ATP-binding site) across the coding 
region of the core component of the NMD pathway, UPF1 (Figures1C, 2, and S2). As an example, 
ovarian cystadenocarcinoma, the missense mutation rate was relatively low, but a relatively high rate 
of gene amplification was observed (Figure S8), suggesting that the UPF1 activity might be amplified 
in this particular cancer type. However, any statistically significant  
co-amplification of UPF1 or the UPF1 binding protein UPF2 (Figure S8) was lacking. This suggests 
that any one of these two components of the NMD pathway might be rate-limiting, and the 
amplification of UPF1 or UPF2 might be sufficient to stimulate the core UPF1 function. Thus, this 
ovarian cancer type might be an attractive target for UPF1 drug leads, under conditions in which 
patients have an UPF1 or UPF2 amplification that stimulates the UPF1-dependent NMD pathway.  
Analysis of other cancer types using TCGA has shown a similar selectivity to ovarian cancer; in 
lung cancer or esophageal cancer, the total amplification rate was lower than that for ovarian cancer, 
but the missense mutation rate was higher in either UPF1 or UPF2 (Figure S8). However, these 
missense mutation cases lack confident data as to whether the mutations are loss or  
gain-of-function. This complicates the utility of using genetic mutation of UPF components from 
cancer genome sequencing as an argument for stratifying patients for trials with UPF1 drug leads. As 
such, we focused this current study on understanding the effects of missense mutations in the core 
NMD component and UPF1 protein, and we will consider performing similar analysis on other NMD 
components in the future that may include UPF2 and SMG genes. In this study, different oncogenic 
mutations at the ATP-binding sites/substrate pocket of UPF1 and at its interface with UPF2 (CH-
domain) were assessed using MD simulations, for their effects on the associated molecular properties 
and interactions, as well as on protein stability. Initial in silico stability screening of cancer associated 
mutations resulted in the identification of five promising and important mutations: K164R, R253W, 
T499M, E637, and E833K. We characterized these mutations for effects on stability as potential gain 
or loss-of-function attributes. 
A first insight was obtained when comparing the structural stability of the wild-type and the 
mutant forms of the UPF1 protein in its apo state. The RMSD values for the apo wild-type, E637K, 
and E833K systems were higher compared to when complexed with AMPPNP, whereas the reverse 
was observed for T499M, K164R, and R253W mutant systems. In addition, residues in the CH-domain 
(between 116 and 295) of UPF1 that bind UPF2 were highly mobile (i.e. in RMSF) compared to any 
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other domain of the UPF1 protein. Concerning the substrate pocket of the UPF1 protein, residues 
T499 and E833 have different RMSFs in UPF1 apo-form/AMPPNP bound and wild-type/mutant 
UPF1, whereas the mobility of the residue E637 remains the same (RMSF ~1 Å) in all these systems. 
Principal component analysis of the first eigenvector identified that the absence of UPF2 or AMPPNP 
(apo-state) drives the movement of the UPF1 CH-domain towards the helicase-domain. Moreover, in 
the UPF1 ATP-site mutants, motions of the CH-domain were observed for T499M and E833K 
complexed with AMPPNP compared to the apo-form, whereas mutant E637K showed the reverse 
behavior. Overall, the UPF1 CH-domain mutant systems obtained well defined clusters when 
complexed with UPF2 than in the apo-state. Such data also highlight the opportunity to take these 
dynamic conformational variations into consideration when developing drug screens that target 
various biochemical properties of the UPF1 protein. 
Hydrogen bonding analysis provided additional insights into the likely mode of action of UPF1. 
This screen identified UPF1 substrate binding site mutant systems that have fewer H-bonds (~4) 
when in complex with AMPPNP, compared to the wild-type UPF1 (~8), whereas the CH-domain 
mutant systems (K164R/R253W) have increased UPF1-UPF2 interactions (~8–10/14–16 H-bonds) 
compared to the wild-type system (~5). In particular, mutation of residue at position 164 (K164R) in 
UPF1 enhanced its H-bond interactions with UPF2 that were absent in the wild-type system, and this 
interaction was enabled as a result of a conformational change of the UPF2 protein. The UPF1 
residues S152, S203, S205, and Q230 formed H-bonds with UPF2 in all UPF1-UPF2 complexes, and 
the residue R703 formed H-bonds with AMPPNP in all UPF1-AMPPNP systems. As with RMSD 
values, insights into hydrogen bonding dynamics can be tested when developing new chemical 
biology tools/functional assays to investigate the functional dynamics of the UPF1 protein in the 
future such as hydrogen deuterium exchange mass spectrometry. 
Finally, MDS data suggest a dominant impact of potential phosphorylation of the Serine residues 
in UPF1 at position 152, 203, and 205 that may modulate the interactions between UPF1 and UPF2. 
Furthermore, residues that formed interactions with AMPPNP in WT UPF1 system and at least one 
mutant system were: G495, T496, G497, K498, T499, K533, and G831. The mutated residues K637 and 
K833 formed H-bond interactions with AMPPNP, whereas the mutant M499 lacked such interactions 
with AMPPNP. The residue level contributions in binding energy (∆E) suggest that the UPF1 residues 
positioned at 637 and 833 contributed more binding energy to AMPPNP in their mutant forms (E637K 
and E833K) compared to their native state, while T499M had lower binding energy with AMPPNP 
compared to the wild-type. The MDS findings suggest that the side-chain of the T499M mutant 
prevents the tri-phosphate moiety of the AMPPNP molecule forming optimal interactions in the 
substrate binding site of UPF1, and this has the potential to affect the ATP-hydrolysis process of UPF1 
or the NMD machinery. 
4. Materials and Methods 
4.1. System Setup 
The crystal structures of UPF1 (PDB: 2WJY [10]) and UPF1-UPF2 (PDB: 2WJV [10]) were used to 
prepare the apo-form/-state of UPF1 and the complex, respectively. The structure of UPF1 bound to 
AMPPNP (ATP analogue, PDB: 2GJK [19]) lacks the CH-domain and therefore, the position of 
AMPPNP was used as a template to prepare AMPPNP bound to the ATP pocket of UPF1 with the 
CH-domain included (PDB: 2WJY [10]). Structures with unresolved residues as shown in Figure S1, 
were modeled using the “prepare protein” protocol implemented in the macromolecules module of 
BIOVIA Discovery Studio Client v18.1 program [Dassault Systemes, BIOVIA Corp., San Diego, CA, 
USA]. This protocol prepares the protein by inserting missing atoms in incomplete residues, models 
missing loop regions, deletes alternate conformations of residues (disorder), removes waters, 
standardizes atom names, and protonates titratable residues using the program pKa [37]. The 
protocol was applied with the CHARMM forcefield and to assign protonation states the following 
parameters were used: pH 7.4, protein dielectric constant 10, and ionic strength 0.145 mM. Protein 
structure preparation was followed by energy minimization using 1000 steps of the "smart 
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minimizer" algorithm with a dielectric constant of 1.0 in BIOVIA Discovery Studio Client v18.1. The 
non-bonded list radius was set to 14 Å for electrostatic and van der Waals interactions, and the  
non-bond higher/lower cut-off distance was 12/10 Å, respectively. In addition, the RMS gradient was 
set to 0.1 in the minimization. 
4.2. Residue Scanning/Site-Directed Mutagenesis 
Mutant models were generated and predicted changes in stability were computed using the 
“residue scan” module from the Molecular Operating Environment (MOE; Chemical Computing 
Group Inc., Montreal, QC, Canada) program. For each studied structure of UPF1 (apo-form and with 
AMPPNP/UPF2), one residue was mutated at a time, and the resulting stability change (∆∆G) upon 
mutation was calculated. “Residue scan” in MOE was performed using LowModeMD ensemble, 
10000 search iterations, and the CHARMM27 forcefield. The stability of a mutant was computed as 
the relative binding free energy difference (∆∆Gbind) between the mutant and wild-type (WT) UPF1 
protein. In detail, ∆∆G is the relative thermostability of the mutation with respect to the wild-type 
UPF1 protein, calculated as the Boltzmann average of the relative stabilities of the ensemble. A 
negative ∆∆G points to a stabilizing mutation while a positive ∆∆G suggests a destabilizing mutation 
[38]. 
4.3. Molecular Dynamics Simulations 
Molecular dynamics simulations were performed for the UPF1 protein in its wild-type forms 
(apo, UPF1-AMPPNP, and UPF1-UPF2), as well as for the mutant proteins with mutated residues 
K164R (located in the UPF1-UPF2 interface) and R253W (placed in the CH-helicase interface) in the 
CH-domain (apo-form and UPF1-UPF2 complex). In addition, MDS were also performed for the 
mutations in the ATP-binding site or the substrate pocket including T499M, E833K and E637K (apo-
form and UPF1-AMPPNP complex), as these residues were speculated to modulate the ATP-binding 
or the hydrolysis process. The GROMACS 4.6.5 [39,40] program was used to perform MDS (for 13 
model systems) by applying the Gromos96 43a1 forcefield [41]. For the AMPPNP molecule, the 
topologies were generated using the PRODRG server as it is compatible with the GROMACS 
program [42]. Moreover, Gaussian 09 (revision E.01) package [43] was used to optimize the 
geometries and to calculate the partial charges of AMPPNP. The charges were acquired by fitting the 
electrostatic potential to fixed charges using the “charges from electrostatic potentials” with a grid-
based method (CHELPG). The obtained CHELPG charges for AMPPNP were suitable for MD 
simulations as they capture higher order effects arising from dipoles [44]. 
The prepared model systems/structures were solvated using a simple point charge (SPC) water 
molecules in a dodecahedron box (10 Å thick). Periodic boundary conditions were applied and the 
simulation systems were neutralized with the appropriate number of Na+ and Cl- counter ions 
(corresponding to a physiological salt concentration of 150 mM; Figure S1C). To relax any steric 
clashes, the system was subjected to energy minimization through 50000 steps of the steepest descent 
algorithm. The particle mesh Ewald (PME) method [45] was used to treat long-range electrostatic 
interactions, and the LINCS algorithm [46] was used to constrain the bond lengths. The cutoff radii 
for van der Waals and Coulomb interactions were set to 10 Å. The system was subsequently 
equilibrated in an NPT (isobaric-isothermal) ensemble simulation for 1000 ps. Standard temperature 
(300 K) and pressure (1 bar) were maintained by applying a V-rescale thermostat [47] and a 
Parrinello–Rahman barostat [48], respectively. Finally, a production run was performed for 1000 ns 
using a leapfrog integrator [49]. The trajectories were saved every 10 ps and analyzed using 
GROMACS tools and VMD [50]. The cutoffs to define H-bonds were 3.5 Å for the donor-acceptor 
distance, and 160°–180° for the intermolecular angle between donor-H-acceptor atoms. 
Binding energies (ΔG) were estimated by subjecting the MDS to molecular mechanics/Poisson–
Boltzmann surface area (MM-PBSA) evaluations using the g_mmpbsa program [51]. Protein–protein 
or protein–ATP binding energies were calculated for snapshots sampled every 1 ns of the 1000 ns 
simulations for the UPF1-AMPPNP and UPF1-UPF2 complexes. Computing the binding energy 
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using g_mmpbsa [51] excludes the entropy contribution. Furthermore, to study the global motion of 
wild-type and mutant UPF1 in apo-forms and UPF1-AMPPNP/UPF2 complexes, principal 
component analysis (PCA) was carried out. This method reduces the complexity of the data and 
extracts motions from the MD trajectory that are functionally significant [52]. The calculation of the 
eigenvectors and eigenvalues was carried out using the g_cover module of the GROMACS software 
utilities, by diagonalizing the covariance matrix, and the g_anaeig tool was used to analyze and plot 
the eigenvectors [53]. 
5. Conclusions 
The cancer genomic sequencing data suggests that residues in the ATP-binding site and  
CH-domain (i.e. UPF2 interacting interface) of the UPF1 protein are frequently mutated, and we 
assessed the effects of those mutations on UPF1using in silico methodologies. The most promising 
key residues of UPF1 were identified by MDS and were in common (wild-type as well as mutant 
systems) in forming hydrogen bond interactions with UPF2 or AMPPNP as follows: S152, S203, S205, 
and Q230 or R703, respectively. Residues G495, T496, G497, K498, T499, K533, and G831 formed 
interactions with AMPPNP in wild-type and in at least one mutant system. Based on our findings, 
we suggest that phosphorylation of the Serine residues at position 152, 203, and 205 in UPF1 may 
modulate/control UPF1-UPF2 interactions/binding.  
The CH-domain K164R and R253Wmutant systems present as well-defined conformational 
clusters when complexed with UPF2 compared to the apo-state, and have increased UPF1-UPF2 
interactions compared to the wild-type system. Moreover, the E637K and E833K alleles in the UPF1 
substrate binding site improved the affinity of AMPPNP for the UPF1 protein, whereas the T499M 
mutant hindered the tri-phosphate moiety of AMPPNP informing optimal interactions with UPF1. 
Altogether, our analysis of the structural changes in different UPF1 systems suggests the flexible 
nature of the substrate binding region in UPF1 with a predictable impact by certain cancer-associated 
mutations. These in silico site-directed mutagenesis findings can be useful in understanding the 
molecular mechanisms of important NMD components (i.e. UPF1 and UPF2) as well as to guide 
future experimental studies that aim to develop chemical tools to impact on UPF1-dependent 
processes. 
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Abbreviations 
NMD nonsense-mediated mRNA decay 
mRNAs messenger RNAs 
PTCs premature termination codons 
eRF1 eukaryotic release factor 1 
UPF1 up frameshift 1 
DHX34 DEAH box polypeptide 34 
SMG1C suppressor with morphological effect on genitalia 1 complex 
EJC exon junction complex 
CCR4 carbon catabolite repressor protein 4 
DCPC decapping complex 
PNRC2 pro-rich nuclear receptor co-activator 2 
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CH-domain cysteine-histidine-rich domain 
SF1 superfamily 1 
nsSNPs non-synonymous single nucleotide polymorphism 
MDS molecular dynamics simulations 
MOE Molecular Operating Environment 
WT wild-type 
SPC simple point charge 
PME particle mesh Ewald 
MM-PBSA molecular mechanics/Poisson-Boltzmann surface area 
PCA principal component analysis 
P bodies processing bodies 
TCGA the cancer genome atlas 
RMSD root mean square deviation 
RMSF root mean square fluctuation 
Rg radius of gyration 
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